Related Experiment Videos
Complications and risks in hematopoietic stem cell transplant patients
1Department of Clinical Laboratory Sciences, University of Texas Health Science Center, San Antonio TX 78299-3900, USA. smithla@uthscsa.edu
Summary
Hematopoietic stem cell transplantation (HSCT) treats hematologic diseases but carries risks of infection and graft-vs-host disease. Neutropenia is a key factor influencing infection type and severity post-HSCT.
Area of Science:
- Hematology
- Transplantation Immunology
- Infectious Diseases
Background:
- Hematopoietic stem cell transplantation (HSCT) is a vital treatment for hematological malignancies, solid tumors, and immunologic disorders.
- Key complications of HSCT include infections and graft-vs-host disease (GVHD).
- Infections post-HSCT can be bacterial, viral, fungal, or protozoan, with distinct onset patterns.
Purpose of the Study:
- To review the risks of infection and graft-vs-host disease following hematopoietic stem cell transplantation.
- To identify predisposing factors influencing infection types and severity.
- To discuss current strategies for preventing and managing these complications.
Main Methods:
- Review of existing literature on hematopoietic stem cell transplantation outcomes.
- Analysis of factors contributing to infection and GVHD development.
- Evaluation of novel preventative and therapeutic approaches.
Main Results:
- Bacterial infections are common early post-HSCT (within 30 days), while viral infections typically manifest later (within 3 months).
- Severe neutropenia post-HSCT is a significant risk factor for infection type and severity.
- Graft-vs-host disease is specific to allogeneic HSCT recipients.
Conclusions:
- Understanding predisposing factors, particularly neutropenia, is crucial for managing HSCT complications.
- Advancements in antimicrobial/antiviral therapies and HSCT manipulation aid in infection and GVHD prevention/control.
- Continued research into HSCT complications is essential for improving patient outcomes.